Alamar Biosciences, Inc. (ALMR)
NASDAQ: ALMR · Real-Time Price · USD
32.70
-1.54 (-4.50%)
At close: Aug 24, 2026, 4:00 PM EDT
33.34
+0.64 (1.96%)
After-hours: Aug 24, 2026, 6:46 PM EDT

Alamar Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
100.4274.2125.14
Revenue Growth
-195.17%-
Cost of Revenue
41.5132.5116.54
Gross Profit
58.9141.718.61
Selling, General & Admin
52.5435.5718.94
Research & Development
47.1137.4739.23
Operating Expenses
99.6573.0458.18
Operating Income
-40.74-31.33-49.57
Interest Expense
-0.75-0.4-2.08
Interest & Investment Income
3.162.164.68
Currency Exchange Gain (Loss)
-0.320.42-0.09
Pretax Income
-48.63-29.15-47.06
Income Tax Expense
1.040.670.01
Net Income
-49.66-29.82-47.07
Preferred Dividends & Other Adjustments
---0.8
Net Income to Common
-49.66-29.82-46.27
Net Income Growth
---
Shares Outstanding (Basic)
241211
Shares Outstanding (Diluted)
241212
Shares Change
--2.89%-
EPS (Basic)
-2.10-2.58-4.40
EPS (Diluted)
-2.10-2.59-4.60
EPS Growth
---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-68.64-58.98-58.16
Free Cash Flow Per Share
-2.90-5.11-4.89
Gross Margin
58.66%56.20%34.23%
Operating Margin
-40.57%-42.22%-197.15%
Profit Margin
-49.45%-40.18%-184.03%
Free Cash Flow Margin
-68.35%-79.48%-231.33%
EBITDA
-37.48-28.57-47.27
EBITDA Margin
-37.33%-38.50%-188.03%
D&A For EBITDA
3.262.762.29
EBIT
-40.74-31.33-49.57
EBIT Margin
-40.57%-42.22%-197.15%
Revenue as Reported
100.4274.2125.14
Advertising Expenses
-1.50.9
SEC Filings: 10-K · 10-Q